ArticleTurk gogus kalp damar cerrahisi dergisi2025
Prediction of STAS positivity in operable non-small cell lung cancer.
Article in Turk gogus kalp damar cerrahisi dergisi, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aims to identify clinical and pathological factors associated with spread through air spaces (STAS) positivity in patients with non-small cell lung cancer. Methods: Between September 2001 and November 2024, a total of 380 patients (279 males, 101 females; mean age: 61.6±10.1 years; range, 20 to 87 years) who were diagnosed with primary lung cancer and underwent surgical resection were retrospectively analyzed. Demographic, clinical, and pathological data of the patients were collected and their association with STAS positivity was evaluated. Results: A higher preoperative monocyte count was significantly associated with STAS positivity (0.73±0.63 vs. 0.58±0.22; p=0.003; odds ratio=5.57; 95% confidence interval: 1.76-17.6). Pathological N1 and N2 stages, along with increased maximum standardized uptake value (SUV Conclusion: Adenocarcinoma histology and increased preoperative monocyte levels are independent predictors of STAS in patients with non-small cell lung cancer. Elevated SUV
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.